Tags

Type your tag names separated by a space and hit enter

Decreased beta-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration.
J Neurol Sci 2005; 237(1-2):61-5JN

Abstract

Several previous studies have identified biochemical markers for Alzheimer's disease (AD): cerebrospinal fluid (CSF)-beta-amyloid peptide42 (CSF-Abeta42), CSF-total tau protein (CSF-tau) and CSF-phosphorylated tau protein (CSF-ptau). Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) as well as AD are diseases with tauopathies. CSF-Abeta42, CSF-tau, and CSF-ptau have not been rigorously investigated in PSP and CBD. In the present study, we assessed CSF-Abeta42, CSF-tau, and CSF-ptau as biochemical markers for PSP and CBD, compared with AD. The subjects consisted of 18 cases of PSP, 9 cases with CBD, 69 cases with AD, and 43 control subjects. Genotyping or phenotyping of apolipoprotein E (apoE) was also performed. CSF-Abeta42 levels were significantly decreased in patients with PSP and CBD as well as in AD patients. The ratio of CSF-ptau to CSF-Abeta42 provided high diagnostic accuracy to distinguish both PSP from AD, and CBD from AD. ApoE genotype/phenotype was not associated with CSF-Abeta42 levels in all groups. We concluded that CSF-Abeta42 levels are reduced in PSP and CBD as well as in AD.

Authors+Show Affiliations

Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Science, 13-1, Takara-machi, Kanazawa 920-8640, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15992827

Citation

Noguchi, Moeko, et al. "Decreased Beta-amyloid Peptide42 in Cerebrospinal Fluid of Patients With Progressive Supranuclear Palsy and Corticobasal Degeneration." Journal of the Neurological Sciences, vol. 237, no. 1-2, 2005, pp. 61-5.
Noguchi M, Yoshita M, Matsumoto Y, et al. Decreased beta-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration. J Neurol Sci. 2005;237(1-2):61-5.
Noguchi, M., Yoshita, M., Matsumoto, Y., Ono, K., Iwasa, K., & Yamada, M. (2005). Decreased beta-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration. Journal of the Neurological Sciences, 237(1-2), pp. 61-5.
Noguchi M, et al. Decreased Beta-amyloid Peptide42 in Cerebrospinal Fluid of Patients With Progressive Supranuclear Palsy and Corticobasal Degeneration. J Neurol Sci. 2005 Oct 15;237(1-2):61-5. PubMed PMID: 15992827.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Decreased beta-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration. AU - Noguchi,Moeko, AU - Yoshita,Mitsuhiro, AU - Matsumoto,Yasuko, AU - Ono,Kenjiro, AU - Iwasa,Kazuo, AU - Yamada,Masahito, PY - 2004/10/20/received PY - 2005/04/14/revised PY - 2005/05/23/accepted PY - 2005/7/5/pubmed PY - 2005/12/13/medline PY - 2005/7/5/entrez SP - 61 EP - 5 JF - Journal of the neurological sciences JO - J. Neurol. Sci. VL - 237 IS - 1-2 N2 - Several previous studies have identified biochemical markers for Alzheimer's disease (AD): cerebrospinal fluid (CSF)-beta-amyloid peptide42 (CSF-Abeta42), CSF-total tau protein (CSF-tau) and CSF-phosphorylated tau protein (CSF-ptau). Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) as well as AD are diseases with tauopathies. CSF-Abeta42, CSF-tau, and CSF-ptau have not been rigorously investigated in PSP and CBD. In the present study, we assessed CSF-Abeta42, CSF-tau, and CSF-ptau as biochemical markers for PSP and CBD, compared with AD. The subjects consisted of 18 cases of PSP, 9 cases with CBD, 69 cases with AD, and 43 control subjects. Genotyping or phenotyping of apolipoprotein E (apoE) was also performed. CSF-Abeta42 levels were significantly decreased in patients with PSP and CBD as well as in AD patients. The ratio of CSF-ptau to CSF-Abeta42 provided high diagnostic accuracy to distinguish both PSP from AD, and CBD from AD. ApoE genotype/phenotype was not associated with CSF-Abeta42 levels in all groups. We concluded that CSF-Abeta42 levels are reduced in PSP and CBD as well as in AD. SN - 0022-510X UR - https://www.unboundmedicine.com/medline/citation/15992827/Decreased_beta_amyloid_peptide42_in_cerebrospinal_fluid_of_patients_with_progressive_supranuclear_palsy_and_corticobasal_degeneration_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0022-510X(05)00198-X DB - PRIME DP - Unbound Medicine ER -